Regulation, Compliance & Legal › Sub-category

Regulatory Approval

1 article

Aurobindo's CuraTeQ Biologics Announces Positive Phase 3 Results for Biosimilar

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced positive top-line results from its Phase 3 trial for its Omalizumab biosimilar, BP11. The Phase 3 study in chronic spontaneous urticaria